Have a personal or library account? Click to login
Simple approach to thieno[3,2-d]pyrimidines as new scaffolds of antimicrobial activities Cover

Simple approach to thieno[3,2-d]pyrimidines as new scaffolds of antimicrobial activities

Open Access
|Jun 2016

References

  1. 1. R. V. Chambhare, B. G. Khase, A. S. Bobde and R. H. Bahekar, Synthesis and preliminary evaluation of some N-[5-(2-furanyl)-2-methyl-4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl]carbox-amide and 3-substituted-5-(2-furanyl)-2-methyl-3H-thieno[2,3-d]pyrimidin-4-ones as antimicrobial agents, Eur. J. Med. Chem. 38 (2003) 89-100; DOI: 10.1016/S0223-5234(02)01442-3.10.1016/S0223-5234(02)01442-3
  2. 2. B. V. Ashalatha, B. Narayana, K. K. V. Raj and N. S. Kumari, Synthesis of some new bioactive 3-amino-2-mercapto-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one derivatives, Eur. J. Med. Chem. 42 (2007) 719-728; DOI: 10.1016/j.ejmech.2006.11.007.10.1016/j.ejmech.2006.11.007
  3. 3. Z. A. Hozien, A. A. Abdel-Wahab, K. M. Hassan, F. M. Atta and S. A. Ahmed, Synthesis of some biologically active agents derived from thieno[2,3-d]pyrimidine derivatives, Pharmazie 52 (1997) 753-758.
  4. 4. H. N. Hafez, H. A. R. Hussein and A. B. A. El-Gazzar, Design, synthesis of substituted thieno[2,3-d] pyrimidine-2,4-dithiones and its S-glycosides analogues as potential antiviral and antibacterial agents, Eur. J. Med. Chem. 45 (2010) 4026-4034; DOI: 10.1016/j.ejmech. 2010.05.060.
  5. 5. L. D. Jennings, S. L. Kincaid, Y. D. Wang, G. Krishna-Murthy, C. F. Beyer, J. P. Mc Ginnis, M. Miranda, C. M. Discafani and S. K. Rabindran, Parallel synthesis and biological evaluation of 5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidin-4(3H)-one cytotoxic agents selective for p21-deficient cells, Bioorg. Med. Chem. Lett. 15 (2005) 4731-4735; DOI: 10.1016/j.bmcl.2005.07.072.10.1016/j.bmcl.2005.07.072
  6. 6. Y. D. Wang, S. Johnson, D. Powell, J. P. McGinnis, M. Miranda and S. K. Rabindran, Inhibition of tumor cell proliferation by thieno[2,3-d]pyrimidin-4(1H)-one-based analogs, Bioorg. Med. Chem. Lett. 15 (2005) 3763-3766; DOI: 10.1016/j.bmcl.2005.05.127.10.1016/j.bmcl.2005.05.127
  7. 7. T. Horiuchi, J. Chiba, K. Uoto and T. Soga, Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone- based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships, Bioorg. Med. Chem. Lett. 19 (2009) 305-308; DOI: 10.1016/j.bmcl.2008.11.090.10.1016/j.bmcl.2008.11.090
  8. 8. A. Angell, C. McGuigan, L. G. Sevillano, R. Snoeck, G. Andrei, E. De Clercq and J. Balzarini, Bicyclic anti-VZV nucleosides, Bioorg. Med. Chem. Lett. 14 (2004) 2397-2399; DOI: 10.1016/j.bmcl.2004.03.029.10.1016/j.bmcl.2004.03.029
  9. 9. A. Brancale, C. McGuigan, B. Algain, P. Savy, R. Benhida, J.-L. Fourrey, G. Andrei, R. Snoeck, E. De Clercq and J. Balzarini, Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity, Bioorg. Med. Chem. Lett. 11 (2001) 2507-2510; DOI: 10.1016/S0960-894X(01)00471-1.10.1016/S0960-894X(01)00471-1
  10. 10. H. N. Hafez, A. B. A. El-Gazzar and G. A. M. Nawwar, Synthesis, biological and medicinal significance of S-glycosido-thieno[2,3-d]-pyrimidines as new anti-inflammatory and analgesic agents, Eur. J. Med. Chem. 45 (2010) 1485-1493; DOI: 10.1016/j.ejmech.2009. 12.056.
  11. 11. A. B. A. El-Gazzar, H. A. R. Hussein and H. N. Hafez, Synthesis and biological evaluation of thieno[2,3-d]pyrimidine derivatives for anti-inflammatory, analgesic and ulcerogenic activity, Acta Pharm. 57 (2007) 395-411; DOI: 10.2478/v10007-007-0032-6.10.2478/v10007-007-0032-618165185
  12. 12. H. N. Hafez, O. K. Al-Duaij and A. B. A. El-Gazzar, Design synthesis and pharmacological evaluation of new nonsteroidal anti-inflammatory derived from 3-aminobenzothieno[2,3-d] pyrimidines, Int. J. Org. Chem. 3 (2013) 110-118; DOI: 10.4236/ijoc.2013.32012.10.4236/ijoc.2013.32012
  13. 13. H. N. Hafez and A. B. A. El-Gazzar, Design and synthesis of 3-pyrazolyl-thiophene, thieno[2,3-d] pyrimidines as new bioactive and pharmacological activity, Bioorg. Med. Chem. Lett. 18 (2008) 5222-5227; DOI: 10.1016/j.bmcl.2008.08.071.10.1016/j.bmcl.2008.08.07118783947
  14. 14. C. J. Shishoo, V. S. Shirsath, I. S. Rathod, M. J. Patil and S. S. Bhargava, Design, synthesis and antihistaminic (H1) activity of some condensed 2-(substituted)-arylaminoethyl-pyrimidine-4-(3H)- ones, Arzneimittel-Forsch. 51 (2001) 221-231; DOI: 10.1055/s-0031-1300028.10.1055/s-0031-1300028
  15. 15. M. Santagati, M. Modica, A. Santagati, F. Russo and S. Spampinato, Synthesis of amino-thienopyrimidine and thienotriazolopyrimidine derivatives as potential anti-convulsant agents, Pharmazie 51 (1996) 7-11.
  16. 16. A. J. Folkes, K. Ahmadi, W. K. Alderton, S. Alix, S. J. Baker, G. Box, I. S. Chuckowree, P. A. Clarke, P. Depledge, S. A. Eccles, L. S. Friedman, A. Hayes, T. C. Hancox, A. Kugendradas, L. Lensun, P. Moore, A. G. Olivero, J. Pang, S. Patel, G. H. Pergl-Wilson, F. I. Raynaud, A. Robson, N. Saghir, L. Salphati, S. Sohal, M. H. Ultsch, M. Valenti, H. J. A. Wallweber, N. C. Wan, C. Wiesmann, P. Workman, A. Zhyvoloup, M. J. Zvelebil and S. J. Shuttleworth, The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer, J. Med. Chem. 51 (2008) 5522-5532; DOI: 10.1021/jm800295d.10.1021/jm800295d
  17. 17. D. P. Sutherlin, L. Bao, M. Berry, G. Castanedo, I. Chuckowree, J. Dotson, A. Folks, L. Friedman, R. Goldsmith, J. Gunzner, T. Heffron, J. Lesnick, C. Lewis, S. Mathieu, J. Murray, J. Nonomiya, J. Pang, N. Pegg, W. W. Prior, L. Rouge, L. Salphati, D. Sampath, Q. Tian, V. Tsui, N. C. Wan, S. Wang, B. Q. Wei, C. Wiesmann, P. Wu, B.-Y. Zhu and A. Olivero, Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer, J. Med. Chem. 54 (2011) 7579-7587; DOI: 10.1021/ jm2009327.10.1021/jm2009327
  18. 18. M. R. Prasad, R. A. Raghuram, R. P. Shanthan, R. K. Subramanian, S. Meena and K. Madhavi, Synthesis and adenosine receptor binding studies of some novel tri-azolothieno-pyrimidines, Eur. J. Med. Chem. 43 (2008) 614-620; DOI: 10.1016/j.ejmech.2007.05.001.10.1016/j.ejmech.2007.05.001
  19. 19. K. A. Chakraborti, B. Gopalakrishnan, M. E. Sobhia and M. Alpeshkumar, 3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors, Bioorg. Med. Chem. Lett. 13 (2003) 1403-1408; DOI: 10.1016/S0960-894X(03)00172-0. 10.1016/S0960-894X(03)00172-0
  20. 20. M. I. Crespo, L. Pages, A. Vega, V. Segarra, M. Lopez, T. Domenech, M. Miralpeix, J. Beleta, H. Ryder and J. M. Palacios, Design, synthesis and biological activities of new thieno[3,2-d]pyrimidines as selective type-4 phosphodiesterase inhibitors, J. Med. Chem. 41 (1998) 4021-4035; DOI: 10.1021/ jm981012m.10.1021/jm981012m9767640
  21. 21. M. Sugiyama, T. Sakamoto, K. Tabata and H. Fukumi, Condensed thienopyrimidine. IV. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidine derivatives, Chem. Pharm. Bull. 37 (1989) 2717-2722; DOI: 10.1248/cpb.37.2717.10.1248/cpb.37.27172611931
  22. 22. A. Gangjee, Y. Qiu, W. Li and R. L. Kisliuk, Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: Classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[ 2,3-d]pyrimidine antifolates, J. Med. Chem. 51 (2008) 5789-5797; DOI: 10.1021/jm8006933.10.1021/jm8006933389276918800768
  23. 23. N. Pemberton, E. Chorell and F. Almqvist, Microwave-assisted synthesis and functionalization of 2-pyridones, 2-quinolones and other ring-fused 2-pyridones, Heterocycl. Chem. 1 (2006) 1-30; DOI: 10.1007/708_006.
  24. 24. S. R. Jain and A. Kar, The antibacterial activity of some essential oils and their combination, Planta Med. 20 (1971) 118-123; DOI: 10.1055/s-0028-109967.
  25. 25. M. J. Weinstein and G. H. Wagman, Plant-derived antibiotics in: Antibiotics Isolation, Separation and urification (Ed. L. A. Mitscher), Elsevier Scientific Publishing Company, Amsterdam 1978, p. 464.
  26. 26. A. L. Barry and C. Thornsbery, Susceptibility testing, in: Manual of Clinical Microbiology (Ed. J. P. Lennette), American Society for Microbiology, Washington (DC) 1981, pp. 561-574.
  27. 27. K. J. Ryan and C. G. Ray (Eds.), Sherris Medical Microbiology, 4th ed., McGraw Hill, New York 2004.
  28. 28. K. M. Amin, M. M. Kamel, M. M. Anwar, M. Khedr and Y. M. Syam, Synthesis, biological evaluation and molecular docking of novel series of spiro [(2H,3H) quinazoline-2,10-cyclohexan]-4(1H)-one derivatives as anti-inflammatory and analgesic agents, Eur. J. Med. Chem. 45 (2010) 2117-2131; DOI: 10.1061/j.ejmech.2009.12.078.
  29. 29. J. Zhang, D. Ren, Y. Ma, W. Wang and H. Wu, CuO nanoparticles catalyzed simple and efficient synthesis of 2,3-dihydroquinazolin-4(1H)-ones and quinazolin-4(3H)-ones under ultrasound irradiation in aqueous ethanol, Tetrahedron 70 (2014) 5274-5282; DOI: 10.1016/j.tet.2014.05.059.10.1016/j.tet.2014.05.059
DOI: https://doi.org/10.1515/acph-2016-0029 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 331 - 351
Accepted on: Feb 25, 2016
Published on: Jun 29, 2016
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2016 Hend N. Hafez, Abdel-Rhman B. A. El-Gazzar, Magdi E. A. Zaki, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.